The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.

Inclusion Criteria:

1. Symptomatic drug refractory paroxysmal (AF episode terminate spontaneously within 7days) who, in the opinion of the investigator, are candidates for ablation for AF

2. 18 years of age or older

3. Able and willing to participate in baseline and follow up evaluations for the fulllength of the sub-study

4. Willing and able to provide informed consent for this sub-study

Exclusion Criteria:

1. Patients who have undergone catheter ablation for atrial fibrillation (PVI, roofline, posterior wall ablation...)

2. Enrolled in an investigational drug or device clinical trial, or any trial thatdictates the treatment plan

3. Persistent or long-standing persistent AF

4. In the opinion of the investigator, any known contraindication to an ablationprocedure